Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+TACE and placebos (PBO)+TACE: EMERALD-1 subgroup analysis - Kröcher, A; Heo, J; Okusaka, T; Yoon, J-H; Sangro, B; Chan, S L; Erinjeri, J P; Matos, M; Decaens, T; Chen, E X; Beg, M S; Matilla, A M; Phuong, LT T; Griffin, R; Udoye, S I; Indiviglio, S; Kudo, M (Zeitschrift für Gastroenterologie, 2025)